Drug intelligence / Profile preview

strep A vaccine + alum

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

A Strep A vaccine formulated with an aluminum-based adjuvant (alum) is a therapeutic candidate designed to prevent infections caused by *Streptococcus pyogenes* (Group A Streptococcus). These vaccines typically employ protein subunit or peptide-based platforms, targeting the highly variable M protein or more conserved surface antigens to elicit protective neutralizing antibodies. The addition of alum (aluminum hydroxide or aluminum phosphate) serves to enhance the magnitude and duration of the immune response by creating a depot effect and stimulating pro-inflammatory pathways. Several such candidates have reached clinical trials, including multivalent M protein vaccines (such as the 30-valent StreptAnova) and conserved peptide conjugates (such as J8-DT and MJ8), aiming to address the global burden of GAS-related diseases such as pharyngitis, impetigo, and life-threatening sequelae like rheumatic heart disease.

Other names
Group A Streptococcus vaccine with aluminum adjuvantGAS vaccine + alumstrep A vaccine + aluminum hydroxidestrep A vaccine + aluminum phosphate
02

Targets

GAC (Group A carbohydrate antigen)M protein (SARS-CoV-2 membrane protein)

Beyond the preview

Go deeper on strep A vaccine + alum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on strep A vaccine + alum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call